jrnls.org logo
Submit

BROWSE ALL JOURNALS

SEE ALL 19 JOURNALS
Indian Journal of Pharmaceutical Education and ResearchNOW IN
Article

Attenuation of Cardiomyopathy Induced in Sub-Chronic Exposure of Acrolein by Sulforaphane via Indirect PPARy Expression Promoter

Promise Madu Emeka1★, Hairul-Islam Mohamed Ibrahim2, Mohamed Aly Morsy1,3, Ibrahim Abdulraham Alhaider1,4, Snawar Hussian5, Emad Abdelaziz Ahmed2,6★ Corresponding author

  1. 1Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa, SAUDI ARABIA.
  2. 2Department of Biological Sciences, College of Science, King Faisal University, Al-Ahsa, SAUDI ARABIA.
  3. 3Department of Pharmacology, Faculty of Medicine, Minia University, El-Minia, EGYPT.
  4. 4R&D, Saudi Food and Drug Authority, Riyadh, SAUDI ARABIA.
  5. 5Department of Biomedical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa, SAUDI ARABIA.
  6. 6Lab of Molecular Physiology, Department of Zoology, Faculty of Science, Assiut University, Assiut, EGYPT.

CORRESPONDENCE

Promise Madu Emeka

Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, SAUDI ARABIA.

pemeka@kfu.edu.sa

Received: 14-10-2021; Revised: 01-11-2021; Accepted: 22-11-2021.

Volume 55, Issue 4 · pp. 1048–1059 · PUBLISHED 2021 · DOI: 10.5530/ijper.55.4.205

View on IJPER original site ↗

ABSTRACT

Sulforaphane (SPN) is reported to activate the Nrf2/Keap1 complex responsible for protein and gene expression promotion of various antioxidant enzymes. The present study examined the role of Nrf2 in modulating other signaling pathways involved in SPN’s attenuation of acrolein (ACL)-induced cardiomyopathy in rats. Forty-two rat was categorized into seven 4-week treatment groups: control, SPN, losartan (LTN), ACL, ACL+SPN, ACL+LTN, and ACL+SPN+LTN. Heart samples were harvested for analysis; cardiac oxidative and injury biomarker levels and histopathological examination were undertaken. PPARγ, Nrf2, NF-κB, COX-2, and CYP2E1 protein expressions were examined. Results show that SPN and SPN+LTN reduced GSH, catalase, and lipid peroxidation compared to the ACL-treated group. Also, levels of creatine kinase-MB, cardiac troponin, and caspase 3 induced by ACL were all attenuated. Altered cardiac tissue pathophysiology by ACL was alleviated. SPN+LTN significantly increased Nrf2 expression via PPARγ action but decreased NF-κB and COX-2 expressions. Also, ACL increased CYP2E1 expression was significantly attenuated by the SPN+LTN combination. For the first time, it suggests that SPN+LTN might offer a better therapeutic alternative to ACL-induced cardiomyopathy by activating Nrf2 via PPARγ and reducing NF-κB/COX-2/CYP2E1 expressions.

KEYWORDS

Open in new tab

REFERENCES

As published

Showing references and in-text citations exactly as published.

    Cite this article

    SELECT FORMAT

    Emeka, P. M., Ibrahim, H. M., Morsy, M. A., Alhaider, I. A., Hussian, S., & Ahmed, E. A. (2021). Attenuation of Cardiomyopathy Induced in Sub-Chronic Exposure of Acrolein by Sulforaphane via Indirect PPARy Expression Promoter. Indian Journal of Pharmaceutical Education and Research, 55(4), 1048–1059. https://doi.org/10.5530/ijper.55.4.205